Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Just thought I would pass this along

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Mar 01, 2021 1:44pm

81 Views

Post# 32686637

RE:RE:RE:RE:Just thought I would pass this along

Another thing to consider is if they go ahead with subcutaneous biweekly injection patients can administer the drug no need to attend clinics.
As per the terms they will pay quarterly towards the principal based on the percentage of the sales plus interest( which should be based on low current rates).
So although it really doesn't make sense to get the committed to huge cost of the protocol the payment will be much more balance sheet friendly.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale